Monoclonal antibody therapy for B cell non-Hodgkin’s lymphomas: emerging concepts of a tumour-targeted strategy CBuske, ...WHiddemann, inEuropean Journal of Cancer, 1999 Although much progress has been made in the understanding of the pathobiology of malignant lymphomas in recent years, progress...
Anti-HGF monoclonal antibody therapy inhibits lung tumorigenesis in transgenic mice overexpressing HGF. 来自 AACR 喜欢 0 阅读量: 27 作者: L Stabile,M Rothstein,S Land,T Luong,J Siegfried 展开 摘要: The hepatocyte growth factor (HGF)/c-Met signaling pathway is involved in lung tumor ...
Overexpression of the RON receptor tyrosine kinase contributes to epithelial cell transformation, malignant progression, and acquired drug resistance. RON also has been considered as a potential target for therapeutic intervention. This study determines
1167 Hepatocyte growth factor (HGF) and its receptor Met are involved in the initiation, progression and metastasis of numerous systemic and CNS tumors. Thus, an anti-HGF monoclonal antibody (mAb) capable of blocking the HGF-Met interaction could have broad applicability in cancer therapy. An ant...
The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combinati
Met activity increases through mutations in the kinase or juxtamembrane domains8-11, through overexpression12, 13, or through binding to its ligand, hepatocyte growth factor (HGF/SF)14, 15. Activating mutations of Met in the germline, which stimulate ligand-independent Met activation, are the ...
The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other
Moreover, some growth factor signalling pathways such as epidermal growth factor (EGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), transforming growth factor (TGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) emerged as critical players in ...
Anti-VEGF therapy in glioma models had demonstrated this before (Rubenstein et al., 2000), and it is therefore likely that current clinical trials will be monitored closely for the locations of recurrent tumors. The receptor for HGF/SF, c-Met, has also been targeted with antibodies,...
(hgf), to induce cell growth, motility and morphogenesis. dysregulation of c-met function, through mut... nr michaud , k tsaparikos , s hillerman ,...- 《cancer research》 被引量: 5 发表: 2006年 generation and screening of monoclonal antibodies for immunopet imaging of igf1r in ...